Stringent Complete Response Criteria for Patients With Multiple Myeloma May Lack Predictive Value
Stringent CR criteria may not predict clinical outcomes for patients with multiple myeloma.
Diagnosis & Disease Information
A Retrospective Look at Drug Sensitivity Before and After Checkpoint Blockade in R/R NHL
Checkpoint-based therapies may sensitize patients to subsequent therapies.
ASH: Carfilzomib increases survival in relapsed multiple myeloma
Improved progression-free survival in relapsed multiple myeloma has been seen with the addition of carfilzomib to lenalidomide and dexamethasone therapy.
CAR cell engineering offers hope for patients with hard-to-treat blood disorders
The use of chimeric antigen receptor (CAR) cell engineering was described in several studies presented at the 2013 ASH Annual Meeting in New Orleans.
Advances in cell engineering improve prognosis of haploidentical stem cell transplantation
Genetically engineered cell therapies may bring hope to patients for whom standard treatments have been unsuccessful, according to two separate studies presented at the 2013 ASH Annual Meeting, in New Orleans, Louisiana.
Genetic driver of Waldenström macroglobulinemia identified
In nearly one-third of patients with Waldenström macroglobulinemia, the disease is switched on by a specific genetic mutation. A new drug that blocks the defective gene can arrest the disease in animal models, according to research reported at the 2013 ASH Annual Meeting, in New Orleans.
Age alone should not limit access to stem cell transplants for patients with MDS
Patients with myelodysplastic syndrome age 66 to 74 years did as well with stem cell transplantation as patients age 60 to 65 years. This research was presented at the 2013 ASH Annual Meeting, in New Orleans.
Drug induces morphologic, molecular, and clinical remissions in myelofibrosis
Imetelstat, a novel telomerase-inhibiting drug, has been found to induce morphologic, molecular, and clinical remissions in some patients with myelofibrosis, according to a new study. The results were presented at the 2013 ASH Annual Meeting, in New Orleans.
Bortezomib regimen improves stem cell transplantation outcomes
Adding bortezomib to standard preventive therapy for GVHD results in improved outcomes for patients receiving stem cell transplants from mismatched and unrelated donors, according to research presented at the 2013 ASH Annual Meeting, in New Orleans.
Targeted treatment reduces relapse in children with AML
Combining the monoclonal antibody gemtuzumab with standard chemotherapy significantly reduced the risk of relapse and increased rates of disease-free survival in pediatric patients with AML. Posttreatment relapse rates are a major indicator of potential for long-term survival in children with the disease.
- Loading...
Loading...
Loading... 
Loading...